 | • レポートコード：MRC2-11QY04132 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は顕性肝性脳症（OHE）のグローバル市場について調査・分析したレポートです。種類別（タイプA（急性肝不全）、タイプB（肝疾患ない体循環バイパス）、タイプC（肝硬変））市場規模、用途別（病院、研究所、診療所、外科センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別顕性肝性脳症（OHE）の競争状況、市場シェア ・世界の顕性肝性脳症（OHE）市場：種類別市場規模 2015年-2020年（タイプA（急性肝不全）、タイプB（肝疾患ない体循環バイパス）、タイプC（肝硬変）） ・世界の顕性肝性脳症（OHE）市場：種類別市場規模予測 2021年-2026年（タイプA（急性肝不全）、タイプB（肝疾患ない体循環バイパス）、タイプC（肝硬変）） ・世界の顕性肝性脳症（OHE）市場：用途別市場規模 2015年-2020年（病院、研究所、診療所、外科センター） ・世界の顕性肝性脳症（OHE）市場：用途別市場規模予測 2021年-2026年（病院、研究所、診療所、外科センター） ・北米の顕性肝性脳症（OHE）市場分析：米国、カナダ ・ヨーロッパの顕性肝性脳症（OHE）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの顕性肝性脳症（OHE）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の顕性肝性脳症（OHE）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの顕性肝性脳症（OHE）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Alfa Wassermann、Cosmo Pharmaceuticals、Horizon Pharma、KannaLife Sciences、Ocer Therapeutics、Rebiotix、Spherium Biomed、Umecrine Cognition、ASKA Pharmaceutical、Mallinckrodt、Valeant ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma.
Overt hepatic encephalopathy develops in approximately 40% of patients with cirrhosis during their clinical care. A first episode of overtencephalopathy predicts recurrence in 40% of patients. Aggravating factors for the development of hepatic encephalopathy in advanced liver disease include infection, gastrointestinal bleeding, metabolic disturbance, and receipt of sedative medications. Genetic abnormalities affecting ammonia metabolism can also play a role.
Market Analysis and Insights: Global Overt Hepatic Encephalopathy Market
The global Overt Hepatic Encephalopathy market size is projected to reach US$ 52 million by 2026, from US$ 49 million in 2020, at a CAGR of 6.4%% during 2021-2026.
Global Overt Hepatic Encephalopathy Scope and Market Size
Overt Hepatic Encephalopathy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Overt Hepatic Encephalopathy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Alfa Wassermann
Cosmo Pharmaceuticals
Horizon Pharma
KannaLife Sciences
Ocer Therapeutics
Rebiotix
Spherium Biomed
Umecrine Cognition
ASKA Pharmaceutical
Mallinckrodt
Valeant
Market segment by Type, the product can be split into
Type A (Acute Liver Failure)
Type B (Portal Systemic Bypass Without Liver Disease)
Type C (Liver Cirrhosis)
Market segment by Application, split into
Hospitals
Research Institutes
Clinics
Surgical Centers
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Overt Hepatic Encephalopathy Revenue
1.4 Market by Type
1.4.1 Global Overt Hepatic Encephalopathy Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Type A (Acute Liver Failure)
1.4.3 Type B (Portal Systemic Bypass Without Liver Disease)
1.4.4 Type C (Liver Cirrhosis)
1.5 Market by Application
1.5.1 Global Overt Hepatic Encephalopathy Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Research Institutes
1.5.4 Clinics
1.5.5 Surgical Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Overt Hepatic Encephalopathy Market Perspective (2015-2026)
2.2 Global Overt Hepatic Encephalopathy Growth Trends by Regions
2.2.1 Overt Hepatic Encephalopathy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Overt Hepatic Encephalopathy Historic Market Share by Regions (2015-2020)
2.2.3 Overt Hepatic Encephalopathy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Overt Hepatic Encephalopathy Market Growth Strategy
2.3.6 Primary Interviews with Key Overt Hepatic Encephalopathy Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Overt Hepatic Encephalopathy Players by Market Size
3.1.1 Global Top Overt Hepatic Encephalopathy Players by Revenue (2015-2020)
3.1.2 Global Overt Hepatic Encephalopathy Revenue Market Share by Players (2015-2020)
3.1.3 Global Overt Hepatic Encephalopathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Overt Hepatic Encephalopathy Market Concentration Ratio
3.2.1 Global Overt Hepatic Encephalopathy Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Overt Hepatic Encephalopathy Revenue in 2019
3.3 Overt Hepatic Encephalopathy Key Players Head office and Area Served
3.4 Key Players Overt Hepatic Encephalopathy Product Solution and Service
3.5 Date of Enter into Overt Hepatic Encephalopathy Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Overt Hepatic Encephalopathy Historic Market Size by Type (2015-2020)
4.2 Global Overt Hepatic Encephalopathy Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Overt Hepatic Encephalopathy Market Size by Application (2015-2020)
5.2 Global Overt Hepatic Encephalopathy Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Overt Hepatic Encephalopathy Market Size (2015-2020)
6.2 Overt Hepatic Encephalopathy Key Players in North America (2019-2020)
6.3 North America Overt Hepatic Encephalopathy Market Size by Type (2015-2020)
6.4 North America Overt Hepatic Encephalopathy Market Size by Application (2015-2020)
7 Europe
7.1 Europe Overt Hepatic Encephalopathy Market Size (2015-2020)
7.2 Overt Hepatic Encephalopathy Key Players in Europe (2019-2020)
7.3 Europe Overt Hepatic Encephalopathy Market Size by Type (2015-2020)
7.4 Europe Overt Hepatic Encephalopathy Market Size by Application (2015-2020)
8 China
8.1 China Overt Hepatic Encephalopathy Market Size (2015-2020)
8.2 Overt Hepatic Encephalopathy Key Players in China (2019-2020)
8.3 China Overt Hepatic Encephalopathy Market Size by Type (2015-2020)
8.4 China Overt Hepatic Encephalopathy Market Size by Application (2015-2020)
9 Japan
9.1 Japan Overt Hepatic Encephalopathy Market Size (2015-2020)
9.2 Overt Hepatic Encephalopathy Key Players in Japan (2019-2020)
9.3 Japan Overt Hepatic Encephalopathy Market Size by Type (2015-2020)
9.4 Japan Overt Hepatic Encephalopathy Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Overt Hepatic Encephalopathy Market Size (2015-2020)
10.2 Overt Hepatic Encephalopathy Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Overt Hepatic Encephalopathy Market Size by Type (2015-2020)
10.4 Southeast Asia Overt Hepatic Encephalopathy Market Size by Application (2015-2020)
11 India
11.1 India Overt Hepatic Encephalopathy Market Size (2015-2020)
11.2 Overt Hepatic Encephalopathy Key Players in India (2019-2020)
11.3 India Overt Hepatic Encephalopathy Market Size by Type (2015-2020)
11.4 India Overt Hepatic Encephalopathy Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Overt Hepatic Encephalopathy Market Size (2015-2020)
12.2 Overt Hepatic Encephalopathy Key Players in Central & South America (2019-2020)
12.3 Central & South America Overt Hepatic Encephalopathy Market Size by Type (2015-2020)
12.4 Central & South America Overt Hepatic Encephalopathy Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Alfa Wassermann
13.1.1 Alfa Wassermann Company Details
13.1.2 Alfa Wassermann Business Overview
13.1.3 Alfa Wassermann Overt Hepatic Encephalopathy Introduction
13.1.4 Alfa Wassermann Revenue in Overt Hepatic Encephalopathy Business (2015-2020))
13.1.5 Alfa Wassermann Recent Development
13.2 Cosmo Pharmaceuticals
13.2.1 Cosmo Pharmaceuticals Company Details
13.2.2 Cosmo Pharmaceuticals Business Overview
13.2.3 Cosmo Pharmaceuticals Overt Hepatic Encephalopathy Introduction
13.2.4 Cosmo Pharmaceuticals Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
13.2.5 Cosmo Pharmaceuticals Recent Development
13.3 Horizon Pharma
13.3.1 Horizon Pharma Company Details
13.3.2 Horizon Pharma Business Overview
13.3.3 Horizon Pharma Overt Hepatic Encephalopathy Introduction
13.3.4 Horizon Pharma Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
13.3.5 Horizon Pharma Recent Development
13.4 KannaLife Sciences
13.4.1 KannaLife Sciences Company Details
13.4.2 KannaLife Sciences Business Overview
13.4.3 KannaLife Sciences Overt Hepatic Encephalopathy Introduction
13.4.4 KannaLife Sciences Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
13.4.5 KannaLife Sciences Recent Development
13.5 Ocer Therapeutics
13.5.1 Ocer Therapeutics Company Details
13.5.2 Ocer Therapeutics Business Overview
13.5.3 Ocer Therapeutics Overt Hepatic Encephalopathy Introduction
13.5.4 Ocer Therapeutics Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
13.5.5 Ocer Therapeutics Recent Development
13.6 Rebiotix
13.6.1 Rebiotix Company Details
13.6.2 Rebiotix Business Overview
13.6.3 Rebiotix Overt Hepatic Encephalopathy Introduction
13.6.4 Rebiotix Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
13.6.5 Rebiotix Recent Development
13.7 Spherium Biomed
13.7.1 Spherium Biomed Company Details
13.7.2 Spherium Biomed Business Overview
13.7.3 Spherium Biomed Overt Hepatic Encephalopathy Introduction
13.7.4 Spherium Biomed Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
13.7.5 Spherium Biomed Recent Development
13.8 Umecrine Cognition
13.8.1 Umecrine Cognition Company Details
13.8.2 Umecrine Cognition Business Overview
13.8.3 Umecrine Cognition Overt Hepatic Encephalopathy Introduction
13.8.4 Umecrine Cognition Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
13.8.5 Umecrine Cognition Recent Development
13.9 ASKA Pharmaceutical
13.9.1 ASKA Pharmaceutical Company Details
13.9.2 ASKA Pharmaceutical Business Overview
13.9.3 ASKA Pharmaceutical Overt Hepatic Encephalopathy Introduction
13.9.4 ASKA Pharmaceutical Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
13.9.5 ASKA Pharmaceutical Recent Development
13.10 Mallinckrodt
13.10.1 Mallinckrodt Company Details
13.10.2 Mallinckrodt Business Overview
13.10.3 Mallinckrodt Overt Hepatic Encephalopathy Introduction
13.10.4 Mallinckrodt Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
13.10.5 Mallinckrodt Recent Development
13.11 Valeant
10.11.1 Valeant Company Details
10.11.2 Valeant Business Overview
10.11.3 Valeant Overt Hepatic Encephalopathy Introduction
10.11.4 Valeant Revenue in Overt Hepatic Encephalopathy Business (2015-2020)
10.11.5 Valeant Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Overt Hepatic Encephalopathy Key Market Segments
Table 2. Key Players Covered: Ranking by Overt Hepatic Encephalopathy Revenue
Table 3. Ranking of Global Top Overt Hepatic Encephalopathy Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Overt Hepatic Encephalopathy Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Type A (Acute Liver Failure)
Table 6. Key Players of Type B (Portal Systemic Bypass Without Liver Disease)
Table 7. Key Players of Type C (Liver Cirrhosis)
Table 8. Global Overt Hepatic Encephalopathy Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Overt Hepatic Encephalopathy Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Overt Hepatic Encephalopathy Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Overt Hepatic Encephalopathy Market Share by Regions (2015-2020)
Table 12. Global Overt Hepatic Encephalopathy Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Overt Hepatic Encephalopathy Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Overt Hepatic Encephalopathy Market Growth Strategy
Table 18. Main Points Interviewed from Key Overt Hepatic Encephalopathy Players
Table 19. Global Overt Hepatic Encephalopathy Revenue by Players (2015-2020) (Million US$)
Table 20. Global Overt Hepatic Encephalopathy Market Share by Players (2015-2020)
Table 21. Global Top Overt Hepatic Encephalopathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overt Hepatic Encephalopathy as of 2019)
Table 22. Global Overt Hepatic Encephalopathy by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Overt Hepatic Encephalopathy Product Solution and Service
Table 25. Date of Enter into Overt Hepatic Encephalopathy Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Overt Hepatic Encephalopathy Market Size by Type (2015-2020) (Million US$)
Table 28. Global Overt Hepatic Encephalopathy Market Size Share by Type (2015-2020)
Table 29. Global Overt Hepatic Encephalopathy Revenue Market Share by Type (2021-2026)
Table 30. Global Overt Hepatic Encephalopathy Market Size Share by Application (2015-2020)
Table 31. Global Overt Hepatic Encephalopathy Market Size by Application (2015-2020) (Million US$)
Table 32. Global Overt Hepatic Encephalopathy Market Size Share by Application (2021-2026)
Table 33. North America Key Players Overt Hepatic Encephalopathy Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Overt Hepatic Encephalopathy Market Share (2019-2020)
Table 35. North America Overt Hepatic Encephalopathy Market Size by Type (2015-2020) (Million US$)
Table 36. North America Overt Hepatic Encephalopathy Market Share by Type (2015-2020)
Table 37. North America Overt Hepatic Encephalopathy Market Size by Application (2015-2020) (Million US$)
Table 38. North America Overt Hepatic Encephalopathy Market Share by Application (2015-2020)
Table 39. Europe Key Players Overt Hepatic Encephalopathy Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Overt Hepatic Encephalopathy Market Share (2019-2020)
Table 41. Europe Overt Hepatic Encephalopathy Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Overt Hepatic Encephalopathy Market Share by Type (2015-2020)
Table 43. Europe Overt Hepatic Encephalopathy Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Overt Hepatic Encephalopathy Market Share by Application (2015-2020)
Table 45. China Key Players Overt Hepatic Encephalopathy Revenue (2019-2020) (Million US$)
Table 46. China Key Players Overt Hepatic Encephalopathy Market Share (2019-2020)
Table 47. China Overt Hepatic Encephalopathy Market Size by Type (2015-2020) (Million US$)
Table 48. China Overt Hepatic Encephalopathy Market Share by Type (2015-2020)
Table 49. China Overt Hepatic Encephalopathy Market Size by Application (2015-2020) (Million US$)
Table 50. China Overt Hepatic Encephalopathy Market Share by Application (2015-2020)
Table 51. Japan Key Players Overt Hepatic Encephalopathy Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Overt Hepatic Encephalopathy Market Share (2019-2020)
Table 53. Japan Overt Hepatic Encephalopathy Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Overt Hepatic Encephalopathy Market Share by Type (2015-2020)
Table 55. Japan Overt Hepatic Encephalopathy Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Overt Hepatic Encephalopathy Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Overt Hepatic Encephalopathy Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Overt Hepatic Encephalopathy Market Share (2019-2020)
Table 59. Southeast Asia Overt Hepatic Encephalopathy Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Overt Hepatic Encephalopathy Market Share by Type (2015-2020)
Table 61. Southeast Asia Overt Hepatic Encephalopathy Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Overt Hepatic Encephalopathy Market Share by Application (2015-2020)
Table 63. India Key Players Overt Hepatic Encephalopathy Revenue (2019-2020) (Million US$)
Table 64. India Key Players Overt Hepatic Encephalopathy Market Share (2019-2020)
Table 65. India Overt Hepatic Encephalopathy Market Size by Type (2015-2020) (Million US$)
Table 66. India Overt Hepatic Encephalopathy Market Share by Type (2015-2020)
Table 67. India Overt Hepatic Encephalopathy Market Size by Application (2015-2020) (Million US$)
Table 68. India Overt Hepatic Encephalopathy Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Overt Hepatic Encephalopathy Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Overt Hepatic Encephalopathy Market Share (2019-2020)
Table 71. Central & South America Overt Hepatic Encephalopathy Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Overt Hepatic Encephalopathy Market Share by Type (2015-2020)
Table 73. Central & South America Overt Hepatic Encephalopathy Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Overt Hepatic Encephalopathy Market Share by Application (2015-2020)
Table 75. Alfa Wassermann Company Details
Table 76. Alfa Wassermann Business Overview
Table 77. Alfa Wassermann Product
Table 78. Alfa Wassermann Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 79. Alfa Wassermann Recent Development
Table 80. Cosmo Pharmaceuticals Company Details
Table 81. Cosmo Pharmaceuticals Business Overview
Table 82. Cosmo Pharmaceuticals Product
Table 83. Cosmo Pharmaceuticals Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 84. Cosmo Pharmaceuticals Recent Development
Table 85. Horizon Pharma Company Details
Table 86. Horizon Pharma Business Overview
Table 87. Horizon Pharma Product
Table 88. Horizon Pharma Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 89. Horizon Pharma Recent Development
Table 90. KannaLife Sciences Company Details
Table 91. KannaLife Sciences Business Overview
Table 92. KannaLife Sciences Product
Table 93. KannaLife Sciences Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 94. KannaLife Sciences Recent Development
Table 95. Ocer Therapeutics Company Details
Table 96. Ocer Therapeutics Business Overview
Table 97. Ocer Therapeutics Product
Table 98. Ocer Therapeutics Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 99. Ocer Therapeutics Recent Development
Table 100. Rebiotix Company Details
Table 101. Rebiotix Business Overview
Table 102. Rebiotix Product
Table 103. Rebiotix Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 104. Rebiotix Recent Development
Table 105. Spherium Biomed Company Details
Table 106. Spherium Biomed Business Overview
Table 107. Spherium Biomed Product
Table 108. Spherium Biomed Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 109. Spherium Biomed Recent Development
Table 110. Umecrine Cognition Business Overview
Table 111. Umecrine Cognition Product
Table 112. Umecrine Cognition Company Details
Table 113. Umecrine Cognition Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 114. Umecrine Cognition Recent Development
Table 115. ASKA Pharmaceutical Company Details
Table 116. ASKA Pharmaceutical Business Overview
Table 117. ASKA Pharmaceutical Product
Table 118. ASKA Pharmaceutical Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 119. ASKA Pharmaceutical Recent Development
Table 120. Mallinckrodt Company Details
Table 121. Mallinckrodt Business Overview
Table 122. Mallinckrodt Product
Table 123. Mallinckrodt Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 124. Mallinckrodt Recent Development
Table 125. Valeant Company Details
Table 126. Valeant Business Overview
Table 127. Valeant Product
Table 128. Valeant Revenue in Overt Hepatic Encephalopathy Business (2015-2020) (Million US$)
Table 129. Valeant Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Overt Hepatic Encephalopathy Market Share by Type: 2020 VS 2026
Figure 2. Type A (Acute Liver Failure) Features
Figure 3. Type B (Portal Systemic Bypass Without Liver Disease) Features
Figure 4. Type C (Liver Cirrhosis) Features
Figure 5. Global Overt Hepatic Encephalopathy Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Research Institutes Case Studies
Figure 8. Clinics Case Studies
Figure 9. Surgical Centers Case Studies
Figure 10. Overt Hepatic Encephalopathy Report Years Considered
Figure 11. Global Overt Hepatic Encephalopathy Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Overt Hepatic Encephalopathy Market Share by Regions: 2020 VS 2026
Figure 13. Global Overt Hepatic Encephalopathy Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Overt Hepatic Encephalopathy Market Share by Players in 2019
Figure 16. Global Top Overt Hepatic Encephalopathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overt Hepatic Encephalopathy as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Overt Hepatic Encephalopathy Revenue in 2019
Figure 18. North America Overt Hepatic Encephalopathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Overt Hepatic Encephalopathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Overt Hepatic Encephalopathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Overt Hepatic Encephalopathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Overt Hepatic Encephalopathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Overt Hepatic Encephalopathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Overt Hepatic Encephalopathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
肝性脳症（HE）治療薬の世界市場（～2026年） HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood. The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutic…- 肝性脳症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Hepatic Encephalopathy Drug Market The global Hepatic Encephalopathy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Hepatic Encephalopathy Drug Scope and Market Size Hepatic E…
- 慢性外傷性脳症（CTE）の世界市場（～2026年） Chronic traumatic encephalopathy (CTE) is a kind of degenerative brain disease that is found in athletes, military veterans, and others with a history of repetitive brain trauma. Market Analysis and Insights: Global Chronic Traumatic Encephalopathy (CTE) Market The global Chronic Traumatic Encephalo…
- 肝硬変の世界市場（～2026年） Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. Alcohol has been identified as the strongest risk factor for liver cirrhosis. Market Analysis and Insights: Global Liver Cirrhosis Market The global Liver Cirrhosis …
- 非アルコール性脂肪肝疾患治療薬の世界市場（～2026年） Nonalcoholic fatty liver disease (NAFLD) is a condition in which excessive fatty accumulation in the hepatocytes. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver …